Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CLARIVATE PLC (CLVT)

Clarivate completes $600 million sale of Life Sciences & Healthcare unit to Altaris

Neutral Impact 4 of 5 m&a Written later

Clarivate completed the sale of its Life Sciences & Healthcare segment to an affiliate of Altaris, LLC on October 6, 2026, for a total value of $600 million, according to the company's press release. The company says it will use the proceeds to reduce debt, and it will update its full year 2026 guidance to reflect the divestiture when it reports third quarter results on November 3, 2026.

Key points

  • Cash paid at closing was $500 million, subject to customary adjustments, plus a $75 million unsecured senior note issued by an Altaris affiliate.
  • A further $25 million of deferred consideration is payable later, no earlier than the conditions tied to transition services and no later than January 31, 2028.
  • Henry Levy, President of Life Sciences & Healthcare, left his subsidiary role at closing under a separation agreement tied to a retention agreement.
  • Clarivate will file pro forma financial statements by October 13, 2026, and report third quarter 2026 results on November 3, 2026.

The filing

CompanyCLARIVATE PLC (CLVT)
Form8-K, current report
Filed with the SECOct 6, 2026, 4:29 PM ET
Accession number0001764046-26-000117

Items reported: 2.01 Acquisition or Disposition Completed5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.